Publications
Early detection of pancreatic cancer by liquid biopsy “PANLIPSY”: A French nation-wide study project. T. Bardol, A. M. Dujon, V. Taly, C. Dunyach-Remy, J-P. Lavigne, B. Costa Silva, K. Kurma, D. Masmoudi, C. Canivet, F. Muscari, B. Bournet, C. Alix-Panabières. BMC Cancer (2024), 24(1):709.
Circulating tumor DNA: A help to guide therapeutic strategy in patients with borderline and locally advanced pancreatic adenocarcinoma ? O. Calliez, D. Pietrasz, F. Ksontini, S. Doat, J-M. Simon, J-C. Vaillabt, V. Taly, P. Laurent-Puig and J-B. Bachet. Digestive and liver disease, S1590-8658(22)00138-4. (2022)
Prognostic value of circulating tumor DNA in metastatic pancreatic cancer patients: post-hoc analyses of 2 randomized trials. Pietrasz, D., Wang-Renault, S., Taieb, T., Dahan, L., Postel, M., Durand-Labrunie, J., Le Malicot, K., Mulot, C., Rinaldi, Y., Phelip, J.M, Doat, S., Blons, H., de Reynies, A., Bachet, JB., Taly, V., Laurent-Puig, P. British Journal of Cancer (2022), 126(3):440-448.
Circulating tumor DNA for prognostication and monitoring in patients with metastatic endometrial carcinoma treated with olaparib: validation in the GINECO-UTOLA trial. Beinse, G., 1 , Taly, V., Leary, A., Baures, A., 4 , Ray-Coquard, I., You, B., Rodrigues , M., Gladieff, L ., Abadie-Lacourtoisie, S., Bengrine-Lefevre, L., Brachet, PE., Lebreton, C., Meynard, G., Fournel, P., Frenel, JS., Selle, F., Largillier, R., Foa, C., Cornila, C., Kaczmarek, E., Hardy-Bessard, AC., D’Hondt, V., Cojean Zelek, I., Roche, S., Duliege, D., Mouret-Reynier, MA., Bouchaert, P., Laurent-Puig, P., Joly, F., Alexandre, J. (2026)
G. Beinse and others, ‘Highly Specific Droplet-Digital PCR Detection of Universally Methylated Circulating Tumor DNA in Endometrial Carcinoma’ Clinical Chemistry (2022), 68(6), 782-793.
Identification of a very-high risk subgroup of localized endometrial carcinoma before surgery using circulating tumor DNA: a proof-of-concept study. Gaudet-Chardonnet, A., Borghese, Alexandre, J., Richard, C., Métairie, L., Reilhac, A., Kime, A., Garinet, S., Parfait, B., Didelot, A., Bourreau, C., Mulot, C., Abdelli, J., de Percin, S., Durdux, C., Chapron, C., Goldwasser, F., Laurent-Puig, P., Taly, V., Beinse, G. International Journal of Gynecological Cancer (2025), 101941. doi: 10.1016/j.ijgc.2025.101941.
Added value in detecting actionable mutations for matcher plasma-based versus tissue next-generation sequencing in advanced non-small cell lung cancer : a retrospective single center analysis on site. Bontoux, C., Lacoux, C., Benzaquen, J., Boutros, J., Rognol, G., Long-Mira, E., Lassalle, S., Allegra, M., Bohly, D., Garcia, M., Bonnetaud, C., Bordone, O., Felix, J-M., Lespinet-Fabre, V., Tanga, V., Marquette, C-H., Taly, V., Baures, A., Heeke, S., Ilié, M., Hofman, V., Hofman, P. Journal of Experimental & Clinical Cancer Research (2025), 44(1):229.
Digital Droplet PCR Assay for Detection and Monitoring of Universally Methylated Circulating Tumor DNA in Sarcoma Patients. Ashton, E., Taly, V., Tlemsani, C., Boudou-Rouquette, P., de Percin, S., Noël, J., Gaudet-Chardonnet, A., Sullo, F., Parfait, B., Abdelli, J., Bruneau, T., Larousserie, F., Audard, V., Larrede, S., Blanchet, B., Waechter, L., Goldwasser, F., Laurent-Puig, P., Alexandre, J., Beinse, G. Clinical Cancer Research (2025), 31(18):3944-3955. doi: 10.1158/1078-0432.CCR-25-0134
Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma. Tougeron, D., Louvet, C., Desramé, J., Evesque, L., Angelergues, A., Carnot, A., Breysacher, G., Zaanan, A., Etchepare, N., Mabro, M., Kaluzinski, L., Petorin, C., Chibaudel, B., Aparicio, T., Bodere, A., Rinaldi, Y., Le Malicot, K., Emile, J-F., Lepage, C., Baures, A., Hanane Djamai, H., Valérie Taly, V., Pierre Laurent-Puig, P. Communications Medicine (2025), 5(1):136. doi: 10.1038/s43856-025-00867-x
Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective study. Bachet JB, Laurent-Puig P, Meurisse A, Bouché O, Mas L, Taly V, Cohen R, Gornet JM, Artru P, Louafi S, Thirot-Bidault A, Baumgaertner I, Coriat R, Tougeron D, Lecomte T, Mary F, Aparicio T, Marthey L, Blons H, Vernerey D, Taieb J. Eur J Cancer (2023), 189:112934. doi: 10.1016/j.ejca.2023.05.022.
The position of circulating tumor DNA in the clinical management of colorectal cancer. Ana Regina de Abreu, Ken Op de Beeck, Valerie Taly, Leonor Benhaim*. Cancers (Basel) (2023), 15(4): 1284. doi: 10.3390/cancers15041284
Clinical impact of circulating tumor DNA to track minimal residual disease in colorectal cancer patients. Hopes and limitations. C Soueidy, A Zaanan, M Gelli, E Moati, C Gallois, V Taly, P Laurent-Puig, L Benhaim, J Taieb. ESMO Gastrointestinal Oncology (2024), 4: 100068. doi.org/10.1016/j.esmogo
Early ctDNA and Survival in Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors: A Secondary Analysis of the SAMCO-PRODIGE 54 Randomized Clinical Trial. Taieb, J., Giulio Sullo, F., Lecanu, A., Bourreau, C., Barbier, E., Gandini, A., Bez, J., Mulot, C., Di Fiore, F., Helajbi, F., Borg, C., Bouché, O., Zaanan, A., André, T., Tougeron, D., Taly, V., Laurent-Puig, P. JAMA oncology (2025), 11(8):874-882. doi: 10.1001/jamaoncol.2025.1646.
L. Benhaim and others, ‘Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS), Eur J of Cancer (2021), 159, 24-33
J. Taieb and others ‘Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial’, Clin Cancer Res (2021);27:5638–46
Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer. E. Moati, H. Blons, V. Taly, F. Garlan, S. Wang-Renault, D. Pietrasz, A. Didelot, G. Sonia, A. Saint, S. Pernot, J. Taieb, P. Laurent-Puig, A. Zaanan. International Journal of Cancer (2020), 15;147(4):1185-1189. Doi: 10.1002/ijc.32657.
J.B. Bachet and others, ‘RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study’, Annals of Oncology (2018), 29 (5), 1211-1219
F. Garlan and others, ‘Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study)’, Clin Cancer Res (2017) 23 (18): 5416–5425.
S. Garrigou and others, ‘A Study of Hypermethylated Circulating Tumor DNA as a Universal Colorectal Cancer Biomarker’, Clinical Chemistry, (2016), 62.8 , 1129–39.